{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:35:10Z","timestamp":1775086510378,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2018.02271","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:59:20Z","timestamp":1537797560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Therapy for Mycobacterium kansasii Infection: Beyond 2018"],"prefix":"10.3389","volume":"9","author":[{"given":"Michelle S.","family":"DeStefano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn M.","family":"Shoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Cynamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1128\/AAC.48.12.4562-4565","article-title":"Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.","volume":"48","author":"Alcaide","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1021\/acs.est.6b05580","article-title":"Mycobacteria in municipal wastewater treatment and reuse: microbial diversity for screening the occurrence of clinically and environmentally relevant species in arid regions.","volume":"51","author":"Amha","year":"2017","journal-title":"Environ. Sci. Technol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e636","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment-shortening of the first-line regimen in a mouse model of tuberculosis.","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01788-17","article-title":"Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium kansasii.","volume":"62","author":"Baku\u0142a","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.36.9.1987","article-title":"Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.","volume":"36","author":"Brown","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ajcp\/23.4.363","article-title":"Human infection with atypical acid-fast organisms.","volume":"23","author":"Buhler","year":"1953","journal-title":"Am. J. Clin. Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1155\/2017\/4545721","article-title":"Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study.","volume":"37","author":"Canueto-Quintero","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects.","volume":"67","author":"Cholo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","article-title":"\u201cActivities of rifampin, rifalazil and azithromycin in a mous model of Mycobacterium kansasii infection,\u201d","author":"Cynamon","year":"2002","journal-title":"Proceedings of the European Society of Mycobacteriology 23rd Annual Congress"},{"key":"B11","article-title":"\u201cComparative in vitro activities of rifampin, rifapentine and rifabutin against Mycobacterium kansasii,\u201d","author":"Cynamon","year":"2013","journal-title":"Proceedings of the European Society of Mycobacteriology 34th Annual Congress"},{"key":"B12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jac\/dkg323","article-title":"Activity of clarithromycin alone and in combination in a murine model of M. kansasii infection.","volume":"52","author":"Cynamon","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","article-title":"\u201cActivities of rifalazil alone and in combination with gatifloxacin in a mouse model of Mycobacterium kansasii infection,\u201d","author":"Cynamon","year":"2003","journal-title":"Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"B14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1099\/jmm.0.45965-0","article-title":"Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.","volume":"54","author":"Da Silva Telles","year":"2005","journal-title":"J. Med. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1128\/AAC.01761-09","article-title":"Moxifloxacin pharmacokinetics\/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.","volume":"54","author":"Deshpande","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease a systematic review and meta-analysis.","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"key":"B17","first-page":"F1","article-title":"\u201cCharacteristic antimycobacterial spectra of the novel anti-TB drug candidates OPC-67683 and PA-824,\u201d","author":"Doi","year":"2006","journal-title":"Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis.","volume":"56","author":"Driver","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/47.4.417","article-title":"Treatment alternatives for Mycobacterium kansasii.","volume":"47","author":"Graybill","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1086\/378742","article-title":"Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii infection.","volume":"37","author":"Griffith","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/jac\/dki111","article-title":"Mycobacterium kansasii subtype I is associated with clarithromycin resistance in china.","volume":"55","author":"Guna","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/infdis\/jir786","article-title":"Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.","volume":"205","author":"Harper","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"B25","first-page":"136","article-title":"\u201cDilemmas and realities in drug susceptibility testing of M. avium-M. intracellulare and other slowly growing nontuberculous mycobacteria,\u201d","author":"Heifets","year":"1991","journal-title":"Drug susceptibility in the chemotherapy of mycobacterial infections"},{"key":"B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF01971272","article-title":"Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.","volume":"11","author":"Hjelm","year":"1992","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NETcollab.","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur. Respir. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/thx.49.5.435","article-title":"Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. research committee, British thoracic society.","volume":"49","author":"Jenkins","year":"1994","journal-title":"Thorax"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.38.7.1455","article-title":"Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17476348.2017.1386563","article-title":"Pulmonary disease by non-tuberculous mycobacteria \u2013 clinical management, unmet needs future perspectives.","volume":"11","author":"Larsson","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.02097","article-title":"Mycobacterium kansasii subtype I is associated with clarithromycin resistance in China.","volume":"7","author":"Li","year":"2016","journal-title":"Front. Microbiol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in nontuberculous mycobacterial infections: a growing niche.","volume":"4","author":"McGuffin","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02627-16","article-title":"In vitro activity of bedaquiline against nontuberculous mycobacteria in China.","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1183\/09031936.00024008","article-title":"Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.","volume":"33","author":"Santin","year":"2009","journal-title":"Eur. Respir. J."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2018.04.4200","article-title":"\u201cComparative in vitro activities of several oxazolidinones against Mycobacterium kansasii,\u201d","author":"Shoen","year":"2018","journal-title":"Proceedings of the 18th International Congress on Infectious Diseases"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/jmm.0.000198","article-title":"Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.","volume":"65","author":"Soni","year":"2016","journal-title":"J. Med. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.2174\/138161211797470192","article-title":"In vitro and in vivo modeling of anti-tuberculosis drugs and its impact on optimization of doses and regimens.","volume":"17","author":"Srivastava","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00248-18","article-title":"Clofazimine for the treatment of Mycobacterium kansasii.","volume":"62","author":"Srivastava","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1128\/AAC.04441-14","article-title":"Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.","volume":"59","author":"Srivastava","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1128\/JCM.41.3.1240-1244.2003","article-title":"Clinical implications of Mycobacterium kansasii species heterogeneity: swiss national survey.","volume":"41","author":"Taillard","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.","volume":"112","author":"Tyagi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B43","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B44","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1128\/AAC.37.9.1997","article-title":"Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.","volume":"37","author":"Witzig","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/34.3.343","article-title":"In-vitro activity of quinolones and macrolides against mycobacteria.","volume":"34","author":"Yew","year":"1994","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.02271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:59:23Z","timestamp":1537797563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.02271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":45,"alternative-id":["10.3389\/fmicb.2018.02271"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2018.02271","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"article-number":"2271"}}